1. In Vivo
  2. >>Market Access

The Oncology Burden Of Proof: Learning From The PD-1 Market

 
• By Lucie Ellis-Taitt

As more and more immuno-oncology products reach the market, the sustainability challenge persists: biopharmaceutical companies are seeking fair reimbursement deals that recognize their innovations, and struggling health care systems worldwide are pushing the burden of proof back onto the shoulders of drug developers.

Experts from consulting group Charles River Associates (CRA) analysed the PD-1/L1 market in Europe to better understand the challenges facing novel immunotherapies when it comes to reimbursement and access. Eva Marchese, vice president at CRA, speaks to In Vivo about the lessons learnt so far for immune-oncology (IO) products when it comes to market access, pricing and value, and how the PD-1 market has laid the reimbursement groundwork for other drug development breakthroughs in cancer.

Pharmaceutical companies developing immune-oncology (IO) drugs are able to move from research and regulatory approval in one indication to several...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from In Vivo

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Podcast: Flagship’s Vision To Predict And Prevent Illness, With Raj Panjabi

 
• By David Wild

Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 
• By Sushmita Panda

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.